Phase 3 Clinical Trials With Primary Completion Dates in September 2021
This is a list of Phase 3 trials with primary completion dates in September 2021 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2021-09-01 | Phase 3 | NCT04181723 | Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™) |
| AGLE | Aeglea BioTherapeutics, Inc. | 2021-09-01 | Phase 3 | NCT03921541 | Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency |
| ANGN | Angion Biomedica Corp. | 2021-09-01 | Phase 3 | NCT02474667 | Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney |
| APLIF | Appili Therapeutics Inc. | 2021-09-01 | Phase 3 | NCT04600895 | The Prevent Severe COVID-19 (PRESECO) Study |
| BBI | Brickell Biotech, Inc. | 2021-09-01 | Phase 3 | NCT03948646 | Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302) |
| FOLD | Amicus Therapeutics, Inc. | 2021-09-01 | Phase 3 | NCT03911505 | ZIP Study - A Study of the Safety, Pharmacokinetics, Efficacy, Pharmacodynamics, and Immunogenicity of ATB200/AT2221 in Pediatric Subjects Aged 0 to < 18 Years With Pompe Disease |
| NBIX | Neurocrine Biosciences, Inc. | 2021-09-01 | Phase 3 | NCT04102579 | Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease |
| NEPH | Nephros, Inc. | 2021-09-01 | Phase 3 | NCT02757872 | Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives |
| PYPD | PolyPid Ltd. | 2021-09-01 | Phase 3 | NCT04233424 | D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection |
| PYPD | PolyPid Ltd. | 2021-09-01 | Phase 3 | NCT03558984 | D-PLEX 302: Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery |
| RDUS | Radius Health, Inc. | 2021-09-01 | Phase 3 | NCT04064411 | Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis |
| SCYX | SCYNEXIS, Inc. | 2021-09-01 | Phase 3 | NCT04029116 | Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) |
| SCYX | SCYNEXIS, Inc. | 2021-09-01 | Phase 3 | NCT03059992 | Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment |
| VNDA | Vanda Pharmaceuticals Inc. | 2021-09-01 | Phase 3 | NCT04028492 | Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis |
| XFOR | X4 Pharmaceuticals, Inc. | 2021-09-01 | Phase 3 | NCT03995108 | Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome |